Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.37 |
| ▸ | NPY1R | P25929 | 7/20 | 0.37 |
| ▸ | NPY2R | P49146 | 5/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.35 |
| ▸ | GNPAT | O15228 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | TFPI | P10646 | 1/20 | 0.33 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8500280 | 1.00 | NPY4R (0.37) | NPY4RNPY5RNPY1RNPY2RITGB3 | |
| SCHEMBL7777201 | 0.92 | EPHX2 (0.39) | NPY4RNPY5RNPY1RNPY2RITGB3 | |
| SCHEMBL17347853 | 0.87 | NPY4R (0.42) | NPY4RNPY5RNPY1RNPY2RKEAP1 | |
| SCHEMBL23104857 | 0.87 | NPY4R (0.47) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL15246044 | 0.86 | NPY4R (0.36) | NPY4RNPY5RNPY1RNPY2RITGB3 | |
| SCHEMBL19791184 | 0.85 | QRFPR (0.38) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL19791180 | 0.85 | QRFPR (0.38) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL23802493 | 0.85 | SIRT5 (0.45) | NPY4RNPY5RNPY1RNPY2RGNPAT | |
| SCHEMBL9112578 | 0.84 | EPHX2 (0.39) | NPY4RNPY5RNPY1RNPY2RITGB3 | |
| SCHEMBL17732656 | 0.84 | GNPAT (0.47) | NPY4RNPY5RNPY1RNPY2RITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9234007-B2 | RGD mimetic γ-AApeptides and methods of use | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-01-12 | — | — | US | disclosed |
| US-20100093612-A1 | INTEGRIN TARGETED CYCLOPEPTIDE LIGANDS, THEIR PREPARATION AND USE | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093612-A1 | INTEGRIN TARGETED CYCLOPEPTIDE LIGANDS, THEIR PREPARATION AND USE | ITGAV, ITGB3, ITGA5 | NPY4R 1465/4885NPY5R 1303/4885NPY1R 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.